$HALO
AI AnalysisGenerated on May 11, 2026
AI Score
Hold$HALO
Halozyme Therapeutics
$HALONASDAQHealthcareMid-Cap
Halozyme develops drug-delivery technologies including ENHANZE for subcutaneous delivery of biologics.
Market Cap
$12.0B
Revenue (TTM)
$0.9B
+15.0%
Net Income (TTM)
$0.35B
+20.0%
EPS (TTM)
$2.50
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$38-$62
Beta
0.72
Dimension Scores
Fundamental
70Technical
68Sentiment
72Risk / Reward
70Momentum
74Financial Health
Profitability
75moderate
Growth
77strong
Liquidity
78strong
Solvency
72strong
Efficiency
68strong
Valuation, technical analysis, investment thesis, risk assessment and more for $HALO
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.